Increased SOCS1 and SOCS3 expression in papillary thyroid carcinoma and its association with prognosis

Basit Öğe Kaydı
dc.contributor.authorEronat, O.
dc.contributor.authorBozdag, Z.
dc.contributor.authorOzturk, S.
dc.contributor.authorAkarsu, E.
dc.date.accessioned2024-08-04T20:59:02Z
dc.date.available2024-08-04T20:59:02Z
dc.date.issued2023
dc.departmentİnönü Üniversitesien_US
dc.description.abstract- OBJECTIVE: The majority of patients with papillary thyroid carcinoma (PTC) have good outcomes, although the identification of new predictors of a poor prognosis would be beneficial. Chronic thyroiditis is a precancerous condition in which proinflammatory cytokines enhance biologically aggressive features. This study investigated the expression of suppressor of cytokine signaling proteins (SOCS) 1 and 3, which are negative feedback inhibitors, in PTC and benign thyroid nodules (BTN), and analyzed the relations among biomarker expression, pathological prognosis, and clinical features. PATIENTS AND METHODS: The pathological materials and clinical data of 100 patients with PTC and 40 with BTN were retrospectively analyzed. Immunohistochemical SOCS1 and SOCS3 staining were performed. Besides comparing SOCS1 and SOCS3 expression between PTC and BTN, we analyzed the expression according to pathological factors and clinical variables. RESULTS: The expression levels of the proteins were significantly higher in PTC than in BTN (p=0.001). SOCS1 expression was higher in older patients with PTC than in younger patients (p=0.001). Unlike SOCS1, SOCS3 was related to the risk group; these groups were distinguished based on the American Thyroid Association (ATA) risk stratification system (p=0.001). SOCS3 was also significantly related to lymph node involvement (p=0.007), capsule invasion (p=0.005), and extrathyroid extension (p=0.009). CONCLUSIONS: The increased SOCS1 and SOCS3 expression in PTC confirms their roles in thyroid carcinogenesis. Antibodies to both SOCS1 and SOCS3 might aid the diagnosis of PTC through immunohistological staining. SOCS3 provides information on lymph node status and aids risk stratification.en_US
dc.identifier.endpage6652en_US
dc.identifier.issn1128-3602
dc.identifier.issue14en_US
dc.identifier.pmid37522675en_US
dc.identifier.startpage6639en_US
dc.identifier.urihttps://hdl.handle.net/11616/103393
dc.identifier.volume27en_US
dc.identifier.wosWOS:001051289100020en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherVerduci Publisheren_US
dc.relation.ispartofEuropean Review For Medical and Pharmacological Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectPapillary thyroid carcinomaen_US
dc.subjectSuppressor of cytokine signaling proteinsen_US
dc.subjectSOCS1en_US
dc.subjectSOCS3en_US
dc.subjectPrognosisen_US
dc.titleIncreased SOCS1 and SOCS3 expression in papillary thyroid carcinoma and its association with prognosisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu